Skip to main content
. 2018 Jul 23;109(9):2822–2829. doi: 10.1111/cas.13708

Figure 2.

Figure 2

Overview of the study population of eribulin‐treated recurrent or metastatic breast cancer patients. Of the 608 starting patient population who had not been treated with granulocyte colony‐stimulating factor, a total of 401 patients were eligible for pharmacodynamic analysis. ALB, serum albumin level; ALP, alkaline phosphatase level; BILI, total bilirubin level; BNEU, absolute neutrophil count at baseline